Publication | Open Access

Synthesis and structure–activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe

Drug TargetBiochemistryBone Morphogenic ProteinMedicineStructure–activity RelationshipsPharmacologyOsteoporosisDrug Discovery